Current Report Filing (8-k)
May 09 2018 - 8:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May
9, 2018 (May 4, 2018)
MYOS RENS TECHNOLOGY INC.
(Exact name of registrant as specified in its
charter)
Nevada
|
|
000-53298
|
|
90-0772394
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
45 Horsehill Road,
Suite 106 Cedar Knolls, New Jersey
|
|
07927
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including area
code
(973) 509-0444
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On
May 4, 2018, MYOS RENS Technology Inc. (the “
Company
”) entered into a research agreement with Weill Cornell
Medical College to study the efficacy of Fortetropin® in preventing weight and muscle loss associated with cancer in a mouse
model of lung cancer. The study will be led by Marcus Goncalves, MD, PhD, at Weill Cornell Medical College, and will use a genetically-engineered
mice model of lung cancer in which mice develop cachexia characterized by reduced weight and lower muscle and fat mass. In this
pre-clinical study, a cohort of adult mice will be induced with lung cancer. Five weeks after induction, 50% of mice will be switched
to a Fortetropin®-infused diet and both groups will be monitored for changes in weight and food intake weekly for 8 weeks.
After 8 weeks, the animals will be dissected for comparative analyses of body composition and skeletal muscle signaling between
the two groups. The Company anticipates that the study will be completed and the results announced in the first quarter of 2019.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
MYOS RENS TECHNOLOGY, INC.
|
|
|
|
Dated: May 9, 2018
|
By:
|
/s/ Joseph Mannello
|
|
Name:
|
Joseph Mannello
|
|
Title:
|
Chief Executive Officer
|
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From Jul 2023 to Jul 2024